Immunity to adeno-associated virus vectors in animals and humans: a continued challenge (Q37127246)

18 August 2017

1 reference

title

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge (English)

1 reference

18 August 2017

0 references

0 references

A K Zaiss

1

1 reference

18 August 2017

D A Muruve

series ordinal

2

1 reference

18 August 2017

publication date

3 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

15

1 reference

18 August 2017

issue

11

1 reference

18 August 2017

page(s)

808-816

1 reference

Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Identification of PDGFR as a receptor for AAV-5 transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Gene targeting in vivo by adeno-associated virus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Precise hit: adeno-associated virus in gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

The interface between innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Intracellular pattern recognition receptors in the host response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Toll-like receptors impact on safety and efficacy of gene transfer vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Type I interferon response against viral and non-viral gene transfer in human tumor and primary cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Retroviral restriction by APOBEC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Complement is an essential component of the immune response to adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Complement amplification revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

The complement system in regulation of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

The complement system in B cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

T-cell regulation: with complements from innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Erythropoietin gene therapy leads to autoimmune anemia in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Autoimmune anemia in macaques following erythropoietin gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Sustained correction of bleeding disorder in hemophilia B mice by gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Major role of local immune responses in antibody formation to factor IX in AAV gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Muscle as a target for supplementary factor IX gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Directed evolution of adeno-associated virus yields enhanced gene delivery vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Adeno-associated virus-mediated gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

CD8(+) T-cell responses to adeno-associated virus capsid in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Immune responses to AAV in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Identification of mouse AAV capsid-specific CD8+ T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Loss of Siglec expression on T lymphocytes during human evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Update on progress and hurdles in novel genetic therapies for hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

7 January 2021

Functional significance of factor H binding to Neisseria meningitidis

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

7 January 2021

Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

7 January 2021

Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

7 January 2021

Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression

1 reference

https://api.crossref.org/works/10.1038%2FGT.2008.54

7 January 2021

Identifiers

DOI

10.1038/GT.2008.54

1 reference

18 August 2017

1 reference